Loading...
SION logo

Sionna Therapeutics, Inc.NasdaqGM:SION Stock Report

Market Cap US$295.7m
Share Price
n/a
1Y-69.0%
7D-87.3%
1D-1.2%
Portfolio Value
​
View

Sionna Therapeutics, Inc.

NasdaqGM:SION Stock Report

Market Cap: US$295.7m

Sionna Therapeutics (SION) Stock Overview

A clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). More details

SION fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Earnings are forecast to decline by an average of 10.3% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years


SION Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW472,568 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
472,568 investors already sharing narratives
View all narratives

Sionna Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sionna Therapeutics
Historical stock prices
Current Share PriceUS$6.46
52 Week HighUS$54.97
52 Week LowUS$4.01
Beta0
1 Month Change-85.44%
3 Month Change-83.94%
1 Year Change-68.97%
3 Year Changen/a
5 Year Changen/a
Change since IPO-74.16%

Recent News & Updates

Seeking Alpha • Aug 12

Sionna's SION-719 Failure Changes Everything (Rating Downgrade)

Summary Sionna Therapeutics is downgraded to Hold after SION-719’s Phase 2a failure, shifting focus to the riskier SION-451 program. SION-719’s lack of efficacy as a Trikafta add-on raises concerns about the NBD1 stabilisation approach’s clinical translation and increases execution risk. SION maintains a strong cash position with $268 million, trading at negative enterprise value, but faces a capital preservation imperative and uncertain pipeline value. Investor attention now centers on whether SION-451 + 2222 can demonstrate efficacy, with management pausing Phase II plans pending a full post-mortem on 719’s failure. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Aug 12

Sionna's SION-719 Failure Changes Everything (Rating Downgrade)

Summary Sionna Therapeutics is downgraded to Hold after SION-719’s Phase 2a failure, shifting focus to the riskier SION-451 program. SION-719’s lack of efficacy as a Trikafta add-on raises concerns about the NBD1 stabilisation approach’s clinical translation and increases execution risk. SION maintains a strong cash position with $268 million, trading at negative enterprise value, but faces a capital preservation imperative and uncertain pipeline value. Investor attention now centers on whether SION-451 + 2222 can demonstrate efficacy, with management pausing Phase II plans pending a full post-mortem on 719’s failure. Read the full article on Seeking Alpha
Analysis Article • Jun 21

Sionna Therapeutics (SION) Stock Looks Fairly Priced After A 157% One Year Run

Recent trading snapshot for Sionna Therapeutics stock Sionna Therapeutics (SION) has drawn attention after recent trading left the stock at a last close of $37.30, with returns mixed across different timeframes and a market value of about $1.68b. See our latest analysis for Sionna Therapeutics. Set against a very strong 1 year total shareholder return of about 157%, Sionna Therapeutics’ recent 30 day share price decline of around 9% and year to date share price slip of roughly 5% suggest some...
Analysis Article • Aug 24

Here's Why We're Not Too Worried About Sionna Therapeutics' (NASDAQ:SION) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

SIONUS BiotechsUS Market
7D-87.3%2.5%1.7%
1Y-69.0%37.4%20.0%

Return vs Industry: SION underperformed the US Biotechs industry which returned 37.4% over the past year.

Return vs Market: SION underperformed the US Market which returned 20% over the past year.

Price Volatility

Is SION's price volatile compared to industry and market?
SION volatility
SION Average Weekly Movement28.3%
Biotechs Industry Average Movement10.1%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.1%

Stable Share Price: SION's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SION's weekly volatility has increased from 17% to 28% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201959Mike Cloonanwww.sionnatx.com

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021.

Sionna Therapeutics, Inc. Fundamentals Summary

How do Sionna Therapeutics's earnings and revenue compare to its market cap?
SION fundamental statistics
Market capUS$295.69m
Earnings (TTM)-US$97.38m
Revenue (TTM)n/a
0.0x
P/S Ratio
-3.0x
P/E Ratio

Is SION overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SION income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$97.38m
Earnings-US$97.38m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-2.15
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did SION perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/14 23:37
End of Day Share Price 2026/08/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sionna Therapeutics, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kambiz YazdiBTIG
Jonathan WollebenCitizens JMP Securities, LLC
Ilya ZubkovFreedom Broker